Common PPARy variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort by Hume, Georgia et al.
Received: 20.08.2012     Accepted: 12.09.2012
J Gastrointestin Liver Dis
December 2012 Vol. 21 No 4, 349-355
Address for correspondence: Georgia E Hume
 IBD Laboratory, QIMR
 Herston Rd, Herston
 Queensland, 4029 
 Australia
 E-mail: georgiaH@qimr.edu.au
Common PPARγ variants C161T and Pro12Ala are not 
Associated with Inflammatory Bowel Disease in an Australian 
Cohort 
Georgia E Hume1,2, Elizabeth V Fowler1, Lyn R Griffiths3, James D Doecke4, Graham L Radford-Smith1,2,5
1) Inflammatory Bowel Diseases Laboratory, Queensland Institute of Medical Research, Herston; 2) Department 
of Gastroenterology and Hepatology, Royal Brisbane & Womens Hospital, Herston; 3) Genomics Research Centre, 
Griffith Institute for Health and Medical Research, Griffith University, Gold Coast, Queensland; 4) CSIRO Preventative 
Health Flagship, CSIRO Mathematics, Informatics and Statistics, RBWH Herston, Queensland; 5) School of Medicine, 
University of Queensland, Herston, Queensland, Australia
Abstract
Background & Aims: Peroxisome proliferator-activated 
receptor (PPAR) γ is a transcription factor, highly expressed 
in colonic epithelial cells, adipose tissue and macrophages, 
with an important role in the regulation of inflammatory 
pathways. The common PPARγ variants C161T and Pro12Ala 
have recently been associated with Ulcerative Colitis (UC) 
and an extensive UC phenotype respectively, in a Chinese 
population. PPARγ Pro12Ala variant homozygotes appear 
to be protected from the development of Crohn’s disease 
(CD) in European Caucasians. Methods: A case-control 
study was performed for both variants (CD n=575, UC 
n=306, Controls n=360) using a polymerase chain reaction 
(PCR)-restriction fragment length polymorphism analysis 
in an Australian IBD cohort. A transmission disequilibrium 
test was also performed using CD trios for the PPARγ 
C161T variant. Genotype-phenotype analyses were also 
undertaken. Results: There was no significant difference 
in genotype distribution data or allele frequency between 
CD and UC patients and controls. There was no difference 
in allele transmission for the C161T variant. No significant 
relationship between the variants and disease location was 
observed. Conclusions: We were unable to replicate in a 
Caucasian cohort the recent association between PPARγ 
C161T and UC or between PPARγ Pro12Ala and an extensive 
UC phenotype in a Chinese population. There are significant 
ethnic differences in genetic susceptibility to IBD and its 
phenotypic expression.
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Introduction
Peroxisome proliferator-activated receptor (PPAR) γ 
is highly expressed in colonic epithelial cells and is an 
effective therapeutic target for PPARγ agonists including 
5-aminosalicylate (5-ASA) in human ulcerative colitis (UC) 
[1]. PPARs are transcription factors, members of the nuclear 
hormone receptor subfamily which regulate transcription of 
other genes by binding to specific DNA sequence elements, 
peroxisome proliferator response elements (PPREs). PPARγ 
is one of three known subtypes with a pivotal role in 
adipocyte differentiation and glucose homeostasis. However, 
PPARγ also controls the expression of genes involved in 
inflammation and cell proliferation. It is bound and activated 
by naturally occurring polyunsaturated fatty acids and 
prostaglandins, as well as by synthetic compounds such 
as thiazolidinediones and non-steroidal anti-inflammatory 
drugs [2]. The highest expression of PPARγ is observed in 
adipose tissue, macrophages and colonic epithelium, all of 
which express all three PPARγ subtypes [3].
The inflammatory bowel diseases are characterized by 
high levels of pro-inflammatory cytokines such as tumour 
necrosis factor-α (TNF-α) and activation of the nuclear 
factor- kappa β (NF-κB) and c-Jun NH2-terminal kinase 
(JNK)/p38 mitogen-activated protein kinase (MAPK) 
pathways. Both these important signaling pathways are 
down regulated by PPARγ activation [4]. In the dextran 
sodium sulfate (DSS) mouse model of colitis, treatment with 
PPARγ ligands, including the thiazolidinedione troglitazone, 
resulted in a significant reduction in inflammation and 
disease severity [5]. Selective PPARγ and retinoid x receptor 
(RXR) agonists have also been shown to significantly 
reduce trinitrobenzene sulfonic acid (TNBS)-induced 
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colitis in a mouse model [6]. Administration of the short 
chain fatty acid butyrate is therapeutic in IBD and PPARγ 
plays an important role in butyrate-mediated inhibition 
of lipopolysaccharide (LPS)-induced NF-қB activation 
[7]. More recently in human studies, rosiglitazone, a 
thiazolidinedione has been efficacious in the treatment of 
mild-moderate UC in a multicenter, randomized, double 
blind, placebo-controlled US study of 105 patients [8]. 
Rosiglitazone also demonstrated therapeutic efficacy in 
mild-moderate UC when combined with 5-aminosalicylate 
in a trial of 42 Chinese patients [9].
PPARγ in the colon is predominantly expressed in the 
epithelial surface layer. Importantly, UC patients have 
very low levels of PPARγ expression in colonic epithelium 
in both inflamed and non-inflamed tissue. Levels are 
however normal in the colonic mucosa in Crohn’s disease 
(CD), in both the inflamed and non-inflamed state. The 
mechanism for this difference is unknown [10]. Toll-like 
Receptor 4 (TLR4), the LPS receptor, is able to regulate 
PPARγ expression, possibly as a negative feedback loop to 
regulate the inflammatory process when stimulated by gram 
negative bacteria in the gut. Therefore in UC where TLR4 is 
upregulated and the expression of PPARγ is impaired, there 
may be loss of tolerance to colonic bacteria and subsequent 
chronic inflammation [4, 10].
It has also been demonstrated that PPARγ and TNFα are 
over expressed by mesenteric adipocytes in patients with CD 
[11]. In view of its role in lipogenesis, dysregulated PPARγ 
expression could contribute to the hypertrophy of mesenteric 
white adipose tissue. This in turn increases TNFα production 
contributing to the local inflammatory response and the 
characteristic mucosal ulcerations of the mesenteric border in 
CD. In addition, PPARγ is markedly upregulated in activated 
macrophages where it antagonizes several pro-inflammatory 
pathways. Hence PPARγ agonists may have a therapeutic 
role in inflammatory disorders including atherosclerosis, 
rheumatoid arthritis and CD [12]. PPARγ is also involved in 
immunoregulation by controlling helper T cell responses as 
well as having an important role in regulatory T cell (Treg) 
function [13, 14]. PPARγ has previously been identified as 
a susceptibility gene in the SAMP1/YitFc Mouse model of 
CD while rare PPARγ alleles have been associated with CD 
in humans [15].
In view of these findings, there has been recent interest 
in the potential role of common mutations in the PPARγ 
gene in the inflammatory bowel diseases. A C→G variant 
in exon 1 of the PPARγ gene (rs1801282), results in the 
substitution of Alanine for Proline at position 12 (Pro12Ala) 
in PPARγ2 [16]. The variant shows decreased binding affinity 
to the cognate promoter element and a reduced ability to 
transactivate responsive promoters. It has been associated 
with decreased receptor activity, lower BMI and improved 
insulin sensitivity [16]. Recently, the variant allele has been 
associated with an extensive UC phenotype in a Chinese 
IBD population [17]. However, a recent meta-analysis 
suggested that European Caucasian patients are afforded 
protection from CD by the AlaAla genotype [18]. A small 
Turkish study of the PPARγ Pro12Ala variant could not 
demonstrate any association with the development of IBD 
[19]. A second frequent polymorphism at position 161 in 
exon 7 of the PPARγ gene (rs 3856806) results from a silent 
C→T substitution. It has been associated with altered plasma 
leptin levels in obese humans, as well as a reduced coronary 
artery disease risk [20, 21]. The variant T allele has been 
associated with UC in a Chinese population although this 
finding was not replicated in a Dutch UC population. No 
specific phenotypic associations were observed [17]. The 
variant T allele also appeared to afford protection from the 
development of colonic adenomas in a Dutch population 
[22]. At odds with this result is the observation of an 
association between the variant allele and colorectal cancer 
in an Indian population [23]. The gene map locus is 3p25, 
some distance from the IBD 9 locus at 3p26 [24]. More 
recently, a genome wide association study has identified 
3p21 as a locus of interest in CD [25].
In view of the physiological characteristics of PPARγ, the 
therapeutic efficacy of PPARγ agonists in IBD, as well as the 
recent association of PPARγ C161T with UC in a Chinese 
population and PPARγ Pro12Ala with protection from CD 
in European Caucasians, we report our own investigation 
into the role of the common PPARγ mutations C161T and 
Pro12Ala in a well-characterised Australian IBD cohort.
Patients and methods
subjects
This candidate gene association study of case–control 
design involved Australian Caucasian patients recruited 
from the IBD Clinical and Research Programme at the 
Royal Brisbane & Women’s Hospital (RBWH), Brisbane, 
Queensland, Australia (CD, n = 575; UC, n = 306) as 
previously described [26]. Informed consent was obtained 
from all patients and the RBWH Human Research Ethics 
Committee approved the study protocol. Patients with 
CD were a consecutive series of patients prospectively 
recruited into a longitudinal IBD research protocol from 
1994. The RBWH is the major IBD referral centre for north 
Brisbane, which encompasses a population of approximately 
800,000. All cases are recorded on an IBD database, together 
with relevant phenotypic information including disease 
distribution, behaviour and duration, surgery, smoking 
and histological data such as granulomas. Phenotypic 
characteristics were carefully determined by two investigators 
using clinical, endoscopic, radiological, histological and 
surgical data available in the patient’s clinical records. The 
investigators were blinded to the patient’s genotype during 
this process. CD phenotyping was based on the Montreal 
Classification but with disease behaviour reclassified as 
stricturing or non-stricturing independent of the presence 
of penetrating disease [27]. Controls (n =360) were healthy 
Caucasian subjects recruited from the east coast of Australia 
over a 4-year period through the Genomics Research Centre 
(Griffith University, Queensland, Australia) as previously 
described [26].
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Genotyping
Genomic DNA was extracted from peripheral blood 
mononuclear cells using the salting-out technique [28]. 
Both polymorphisms were detected using a polymerase 
chain reaction (PCR)-restriction fragment polymorphism 
analysis. For the PPARγ P12A polymorphism, the PCR 
was carried out using Platinum PCR Supermix (Invitrogen 
Australia, Mount Waverley, Victoria, Australia) and the 
primers 5’ GCC AAT TCA AGC CCA GTC 3’ and 5’ GAT 
ATG TTG CAG ACA GTG TAT CAG TGA AGG AAT CGC 
TTT CCG 3’. After amplification (annealing temperature 
620C) the product was digested using BstU1 (New England 
Biolabs, Genesearch, Arundel, Queensland, Australia). The 
enzyme cuts the product when the variant allele is present, 
allowing the two alleles to be identified on a 2.8% agarose 
gel. For the PPARγ C161T mutation, genotyping included 
PCR (annealing temperature 560C) with the primers 5’ CAA 
GAC AAC CTG CTA CAA GC 3’ and 5’ TCC TTG TAG 
ATC TCC TGC AG 3’, followed by digestion with HpyCH4 
IV (New England Biolabs). HpyCH4IV cuts the product in 
the presence of the wild-type allele hence the two alleles can 
be easily distinguished on a 2.5% agarose gel, with ethidium 
bromide for visualisation.
statistical analysis
We compared the frequency of the two PPARγ 
polymorphisms between CD patients, UC patients and 
controls using the Chi Square test; Fisher’s Exact p-
values were utilized where necessary (Table I). Further 
stratifications were conducted for disease location for both 
CD and UC patients (Tables II, III), comparing control 
genotype to each individual sub group. Allele associations 
were also compared. Two tailed p-values of <0.025 were 
considered statistically significant (Bonferroni adjusted 
for multiple comparisons). All statistical analyses were 
conducted using the R statistical software package (R 
Development Core Team, R: A Language and Environment 
for Statistical Computing, Vienna, Austria.). Haploview 
[28] was used to analyse HapMap SNP genotype data (EUR 
in HapMap rel24/phaseII Nov08, on NCBI B36 assembly, 
dbSNP b126).
Results
Genotype and allele distribution 
The genotype distribution data were similar between 
the control group and overall IBD cases for both PPARγ 
Pro12Ala (p=0.97) and C161T (p=0.34). The allele 
frequency of the variant T allele of PPARγ C161T was higher 
in the CD group compared to controls but this did not meet 
statistical significance (0.142 vs 0.115 p=0.09). The variant 
T allele frequency in the UC group was similar to controls 
(0.128 vs 0.115 p=0.72). The allele frequencies for the PPARγ 
Pro12Ala variant G allele did not vary significantly between 
the control group and UC (0.128 vs 0.108 p=0.33) or CD 
(0.128 vs 0.133 p=0.71) (Table I). In all the study groups, 
PPARγ C161T and Pro12Ala were in Hardy-Weinberg 
Equilibrium.
table I. Genotype distribution and allele frequency data for PPARγC161T (rs3856806) and Pro12Ala (rs1801282)
IBD phenotype
 
rs1801282
Genotype
Control
N 
Case
N 
Genotype
Control
Frequency
Case
 Genotype
p-value
Allele
p-value
Overall UC 
association
 
CC 205 243 0.76 0.79
CG 61 60 0.23 0.20
GG 4 3 0.01 0.01 0.61
Minor allele   0.128 0.108  0.33
 rs3856806
Genotype
Control
N 
Case
N 
Genotype
Control
Frequency
Case
Genotype
p-value
Allele
p-value
 CC 284 233 0.79 0.77
CT 71 64 0.20 0.21
TT 6 7 0.02 0.02 0.56
Minor allele   0.115 0.128  0.72
rs1801282
Genotype
Control
N 
Case
N 
Genotype
Control
Frequency
Case
Genotype
p-value
Allele
p-value
Overall CD 
association
 
CC 205 432 0.76 0.75
CG 61 133 0.23 0.23
GG 4 10 0.01 0.02 0.93
Minor allele   0.128 0.133  0.71
rs3856806
Genotype
Control
N 
Case
N 
Genotype
Control
Frequency
Case
Genotype
p-value
Allele
p-value
 CC 284 422 0.79 0.74
CT 71 134 0.20 0.24
TT 6 14 0.02 0.02 0.25
Minor allele   0.115 0.142  0.09
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transmission disequilibrium test
Ninety-nine CD trios were genotyped for the PPARγ 
C161T mutation in view of the findings from the case 
control analysis. Of these, there were 44 informative allele 
transmissions from a non-affected parent to an index CD 
case. There was no difference in allele transmission between 
the wild-type and variant with 50% transmission of each 
allele.
Genotype phenotype relationships 
There was no significant difference in genotype 
distribution or allele frequency for PPARγ Pro12Ala or 
C161T between the CD disease locations, ileum (L1), colon 
(L2) and ileocolon (L3) (Table II). Similarly, we were unable 
to demonstrate any difference in allele frequency or genotype 
distribution for either PPARγ mutation when considering 
disease extent in UC (left-sided vs extensive, Table III). 
The variant T allele for PPARγ C161T was more frequent in 
patients with an extensive UC phenotype however this did 
not meet statistical significance (0.142 vs 0.115; p=0.26).
PPARγ HapMap data
Analysis of PPARγHapMap data in Haploview revealed 
that rs3856806 was not included in any haplotype block 
identified in this gene, although it does show moderate 
linkage disequilibrium (LD; 57-72%) with several SNPs in 
the first haplotype block (including rs1801282; LOD = 4.3, 
r2 = 0.29, D’=0.63) (Data not shown). Haplotype block 1 
spans 73kb at the 5’ end of the gene, and this region also 
contains four intronic PPARγ SNPs, which are in LD with 
rs3856806 (but not block 1) despite being physically distant 
(115-134kb apart). The rs1801282 SNP is in strong LD with 
several SNPs in haplotype block 1.
Discussion
This case control study did not demonstrate any 
significant association between the two common PPARγ 
mutations C161T and Pro12Ala and IBD in an Australian 
patient cohort. We were unable to replicate the recently 
reported association between the variant C161T allele and 
a Chinese UC population, despite larger patient and control 
numbers. This confirms the lack of replication in a Dutch UC 
population of similar numbers. There was also no evidence 
that the PPARγ AlaAla genotype afforded any protection 
from the development of CD. It is notable that the genotype 
frequencies for C161T were similar between Australian 
UC cases and controls, Dutch UC Cases and controls and 
table II. CD Disease location genotype distribution and allele frequency data for PPARγC161T (rs3856806) and Pro12Ala (rs1801282)
Phenotype rs1801282 
Genotype
Control 
N
Case
N
Genotype 
Control
Frequency 
Case
Genotype 
p-value
Allele 
p-value
Location
Ileal
 
 
 
CC 205 174 0.76 0.79
CG 61 43 0.23 0.19
GG 4 4 0.01 0.02 0.68  
Minor allele   0.128 0.115  0.56
Colonic
 
 
 
CC 205 46 0.76 0.82   
CG 61 10 0.23 0.18
GG 4 0 0.01 0.00 0.46  
Minor allele   0.128 0.089  0.26
Ileocolonic
 
 
 
CC 205 24 0.76 0.67   
CG 61 11 0.23 0.31
GG 4 1 0.01 0.03 0.46  
Minor allele   0.128 0.181  0.22
Location rs3856806
Ileal
 
 
 
CC 284 164 0.79 0.75
CT 71 47 0.20 0.21
TT 6 8 0.02 0.04 0.26  
Minor allele   0.115 0.144  0.15
Colonic
 
 
 
CC 284 43 0.79 0.78   
CT 71 11 0.20 0.20
TT 6 1 0.02 0.02 0.99  
Minor allele   0.115 0.118  0.92
Ileocolonic
 
 
 
CC 284 121 0.79 0.76   
CT 71 36 0.20 0.23
TT 6 2 0.02 0.01 0.71  
Minor allele   0.115 0.126  0.62
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Chinese controls. However, the Chinese UC patients had a 
significantly different genotype distribution (Table IV) [17]. 
It is possible that this represents real variation in disease 
pathogenesis between Caucasian and Chinese patients. It is 
well recognized that the major CD susceptibility mutations 
in NOD2/CARD15, IL23R and ATG16L1 do not contribute 
significantly to disease susceptibility in Asian patients 
[13, 14]. Specifically, mutations in NOD2/CARD15 are 
exceedingly rare in Chinese patients [29]. In contrast, SNPs 
within the tumour necrosis factor super family member 15 
(TNFSF15) gene have been significantly associated with 
CD in both Japanese and European IBD populations [27]. 
Hence it is apparent that genetic susceptibility to IBD will 
vary markedly between different ethnic groups, however 
some susceptibility loci will be shared. In addition, the 
phenotype of UC varies considerably between Asian and 
Caucasian patients. Chinese patients predominantly present 
with distal or left-sided disease and have a later age of disease 
onset [30]. Caucasian UC patients are more likely to have 
extensive colitis, a positive family history and a negative 
correlation with cigarette smoking [8]. It is evident therefore, 
that both genetic and environmental factors involved in the 
pathogenesis of the disease will vary significantly between 
Chinese and Caucasian subjects.
The role of genetics in IBD susceptibility is supported 
by epidemiological data and appears to be stronger in CD 
than UC. The greatest risk factor for developing disease 
is having an affected relative, particularly a sibling which 
results in a 13-36 times increased risk of CD, and a 7-17 
times increased risk of UC. In addition, concordance rates 
among monozygotic twins are significantly higher than 
among dizygotic twins and are higher in CD than in UC [31, 
32]. This makes the demonstration of association between 
a particular gene mutation and UC even more difficult. It is 
only recently with the advent of genome-wide association 
studies (GWAS) capable of genotyping very large numbers 
of patients for thousands of single nucleotide polymorphisms 
(SNPs) that multiple clear susceptibility loci for UC have 
been identified [9, 33]. It will clearly be most informative 
to compare the results of GWAS conducted using Chinese 
table III. UC Disease extent genotype distribution and allele frequency data for PPARγC161T (rs3856806) and 
Pro12Ala (rs1801282)
Phenotype rs1801282 
Genotype
Control
N
Case
N
Genotype 
Control
Frequency 
Case
Genotype
p-value 
Allele
p-value
Location
Left-sided disease CC 205 66 0.76 0.73
CG 61 23 0.23 0.26
GG 4 1 0.01 0.01 0.83  
Minor allele   0.128 0.139  0.70
Extensive disease
 
CC 205 98 0.76 0.78   
CG 61 26 0.23 0.21
GG 4 1 0.01 0.01 0.78  
Minor allele   0.128 0.112  0.53
Location rs3856806
Left-sided disease CC 284 71 0.79 0.79
CT 71 15 0.20 0.17
TT 6 4 0.02 0.04 0.24  
Minor allele   0.115 0.128  0.63
Extensive disease
 
CC 284 90 0.79 0.73   
CT 71 31 0.20 0.25
TT 6 2 0.02 0.02 0.43  
Minor allele   0.115 0.142  0.26
table IV. Genotype distribution data for PPARγC161T (rs3856806) in Australian, Dutch and Chinese UC 
patients and Controls.
Australian Australian Dutch Dutch Chinese Chinese
UC Controls UC Controls UC Controls
PPARΥ n = 304 n = 361 n = 302 n = 180 n = 212 n = 220  
C161T
C/C 233 (76.6%) 284 (78.7%) 230 (76.2%) 134 (74.4%) 132 (62.3%) 164 (74.5%)
C/T 64 (21.1%) 71 (19.7%) 69 (22.8%) 43 (23.9%) 75 (35.4%) 55 (25.0%)
T/T 7 (2.3%) 6 (1.7%) 3 (1.0%) 3 (1.7%) 5 (2.3%) 1 (0.5%)
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patients to those in Caucasian populations to more accurately 
determine major ethnic genetic differences. Most recently, a 
GWAS conducted in Japanese UC patients did not identify 
PPARγ C161T (rs3856806) as a site of significant disease 
association [30].
Whilst the allele frequency for the C161T variant 
was higher in CD patients than controls, this result did 
not achieve statistical significance. A lack of association 
was supported by a lack of transmission disequilibrium 
between the wild-type and variant alleles when studying 
family trios for this mutation. In addition, GWAS have not 
demonstrated a significant association between the PPARγ 
locus and CD or UC. The nearest locus with documented 
association in recent GWAS is at 3p21, some distance from 
PPARγ at 3p26 [34]. PPARγ C161T (rs3856806) is a silent 
SNP hence it is assumed to be in linkage disequilibrium 
with a functional mutation nearby in view of its multiple 
previously reported associations. However, a Haploview 
analysis of PPARγHapMap data revealed that rs3856806 is 
not in any haplotype block across the gene, although it does 
show modest LD with several SNPs in block 1, including 
PPARγ Pro12Ala (rs1801282). LD between rs3856806 and 
several distant intronic SNPs in PPARγ was also observed 
but these do not appear to be in a position to influence 
transcription initiation. Hence there does not appear to be 
any functional mutations within the gene that are in strong 
LD with rs3856806.
Conclusions
Whilst we have not been able to demonstrate any 
significant associations between two common PPARγ SNPs 
and CD or UC in an Australian population, the important 
potential therapeutic role for PPARγ agonists should 
not be discounted. With important anti-inflammatory, 
immunoregulatory and possibly tumour suppressive 
functions, the current role of PPARγ agonists in the therapy 
of IBD seems likely to be expanded. In addition, it will be 
exciting to investigate potential differences in the genetic 
susceptibility of UC and CD between Asian, Chinese and 
Caucasian populations with large Asian genome wide 
association studies.
Conflicts of interest
None to declare.
Acknowledgments
Georgia Hume was supported by an NH&MRC 
postgraduate medical scholarship. Elizabeth Fowler was 
supported by the Reginald Ferguson Research Fellowship 
from the University of Queensland. Graham Radford-Smith 
was supported by a Queensland Government Smart State 
Clinical Research Fellowship.
References
 1. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal 
antiinflammatory effect of 5-aminosalicylic acid is dependent on 
peroxisome proliferators-activated receptor-γ. J Exp Med 2005; 201: 
1205-1215.
 2. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions 
of peroxisome proliferator-activated receptor gamma. J Mol Med 
2001; 79: 30-47.
 3. Fajas L, Fruchart JC, Auwerx J. PPARgamma3 mRNA: a distinct 
PPARgamma mRNA subtype transcribed from an independent 
promoter. F E B S Lett 1998; 438: 55-60.
 4. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx 
J, Desreumaux P. Role of peroxisome proliferator-activated 
receptor gamma and retinoid X receptor heterodimer in hepato-
gastroenterological diseases. Lancet 2002; 360: 1410-1418.
 5. Su CG, Wen X, Bailey ST, et al., A novel therapy for colitis utilizing 
PPARγ ligands to inhibit the epithelial inflammatory response. J Clin 
Invest 1999; 104: 383-389.
 6. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon 
inflammation through activators of the retinoid X receptor (RXR)/
peroxisome-activated receptor γ (PPARγ) heterodimer: A basis for 
new therapeutic strategies. J Exp Med 2001; 193: 827-838.
 7. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively 
upregulated in Caco-2 cells by butyrate. Biochem Biophys Res 
Commun 2000; 272: 380-385.
 8. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for 
active ulcerative colitis: a randomized placebo-controlled trial. 
Gastroenterology 2008; 134: 688-695.
 9. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone 
and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 
2008; 14: 114-119.
 10. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of 
peroxisome proliferator-activated receptorg in ulcerative colitis. 
Gastroenterology 2003; 124: 1265-1276.
 11. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations 
in mesenteric adipose tissue in Crohn’s disease. Gastroenterology 
1999; 117: 73-81.
 12. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome 
proliferator-activated receptor-gamma is a negative regulator of 
macrophage activation. Nature 1998; 391: 79-82
 13. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y. 
Absence of mutation in the NOD2/CARD15 gene among 483 
Japanese patients with Crohn’s disease. J Hum Genet 2002; 47: 
469-472.
 14. Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata 
A. Association analysis of genetic variants in IL23R, ATG16L1 and 
5p13.1 loci with Crohn’s disease in Japanese patients. J Hum Genet 
2007; 52: 575-583.
 15. Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxisome 
proliferator-activated receptor-γ in SAMP1/YitFc mice and in human 
Crohn’s disease. Gastroenterology 2005; 128: 351-360.
 16. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in 
PPARg2 associated with decreased receptor activity, lower body 
mass index and improved insulin sensitvity. Nat Genet 1998; 20: 
284-287.
 17. Shrestha UK, Karimi O, Crusius JB, et al. Distribution of peroxisome 
proliferator-activated receptor-gamma polymorphisms in Chinese 
and Dutch patients with inflammatory bowel disease. Inflamm Bowel 
Dis 2009; 16: 312-319.
 18. Zhang ZF, Yang N, Zhao G, Zhu L, Wang LX. Association between 
the Pro12Ala polymorphism of peroxisome proliferator-activated 
receptor gamma 2 and inflammatory bowel disease: a meta-analysis. 
PLos One 2012; 7:e30551.
 19. Atug O, Tahan V, Eren F, et al. Pro12Ala Polymorphism in the 
peroxisome proliferator- activated receptor-gamma ( PPARγ) gene 
Common PPARγ variants in an Australian IBD cohort 355
in inflammatory bowel disease. J Gastrointestin Liver Dis 2008; 17: 
433-437.
 20. Meirhaeghe A, Fajas L, Helbecque N, et al. A genetic polymorphism 
of the peroxisome proliferators-activated receptor γ gene influences 
plasma leptin levels in obese humans. Hum Mol Genet 1998; 7: 
435-440.
 21. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated 
receptorg C161T polymorphism and coronary artery diease. 
Cardiovasc Res 1999; 44: 588-594.
 22. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, 
Kampman E. Colorectal adenoma risk is modified by the interplay 
between pathways in archidonic acid pathway genes and fish 
consumption. Carcinogenesis 2005; 26: 449-457.
 23. Jiang J, Gajalakshmi V, Wang J, et al. Influence of the C161T but no 
the Pro12Ala polymorphism in the peroxisome proliferator-activated 
receptor-gamma on colorectal cancer in an Indian population. Cancer 
Sci 2005; 96: 507-512.
 24. Duerr RH, Barmada MM, Zhang L, et al. Evidence for an 
inflammatory bowel disease locus on chromosome 3p26: linkage, 
transmission/disequilibrium and partitioning of linkage. Hum Mol 
Genet 2002; 11: 2599-2606.
 25. Wellcome Trust Case Control Consortium. Genome-wide association 
study of 14,000 cases of seven common diseases and 3,000 shared 
controls. Nature 2007; 447: 661-678.
 26. Hume GE, Fowler EV, Doecke J, et al. Novel NOD2 haplotype 
strengthens the association between TLR4 Asp299gly and Crohn’s 
disease in an Australian population. Inflamm Bowel Dis 2008; 14: 
585-590.
 27. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide 
polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. 
Hum Mol Genet 2005; 14: 3499-3506.
 28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and 
visualization of LD and haplotype maps. Bioinformatics 2005; 21: 
263-265.
 29. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition 
of commensal microflora by toll-like receptors is required for 
intestinal homeostasis. Cell 2004; 118: 229-241.
 30. Asano K, Matsushita T, Umeno J, et al. A genome-wide association 
study identifies three new susceptibility loci for ulcerative colitis in 
the Japanese population. Nat Genet 2009; 41: 1325-1329.
 31. Tysk C, Lindberg E, Jarnerot G, Flodérus-Myrhed B. Ulcerative colitis 
and Crohn’s disease in an unselected population of monozygotic and 
dizygotic twins A study of heritability and the influence of smoking. 
Gut 1988; 29: 990-996.
 32. Katayama K, Wada K, Nakajima A, et al. A Novel PPAR gamma 
gene therapy to control inflammation associated with inflammatory 
bowel disease in a murine model. Gastroenterology 2003; 124: 
1315-1324.
 33. Zhou X, Kong N, Zou H, et al. Therapeutic potential of TGF-B-
induced CD4+Foxp3+ regulatory T cells in autoimmune diseases. 
Autoimmunity 2011; 44: 43-50.
 34. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association 
defines more than 30 distinct susceptibility loci for Crohn’s disease. 
Nat Genet 2008; 40: 955-962.
